Xiaonian Cao

机构：Luye Pharma (China)

发表论文 38 篇 · 总被引 780 次 · h-index 15

代表论文

• Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer (2019 · Journal of Experimental & Clinical Cancer Research · 被引 87)
• NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein (2021 · Oncogene · 被引 75)
• MiR-363-3p inhibits the epithelial-to-mesenchymal transition and suppresses metastasis in colorectal cancer by targeting Sox4 (2016 · Biochemical and Biophysical Research Communications · 被引 75)
• miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met (2017 · Scientific Reports · 被引 35)
• Cellular Mechanism Underlying Hydrogen Sulfide Mediated Epithelial K+ Secretion in Rat Epididymis (2019 · Frontiers in Physiology · 被引 27)
• miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer (2016 · Journal of Huazhong University of Science and Technology [Medical Sciences] · 被引 26)